Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 2176460, 9 pages
https://doi.org/10.1155/2017/2176460
Research Article

Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients

1Department of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
2Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
3Center of Clinical Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China

Correspondence should be addressed to Xudong Wang; moc.liamtoh@88gnoduxgnaw

Received 5 January 2017; Revised 25 March 2017; Accepted 19 April 2017; Published 8 June 2017

Academic Editor: Andreas Hillenbrand

Copyright © 2017 Can Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Eg5 (kinesin spindle protein) plays an essential role in mitosis. Inhibition of Eg5 function results in cell cycle arrest at mitosis, which leads to cell death. To date, Eg5 expression and its prognostic significance have not been studied in hepatocellular carcinoma (HCC). In this study, 26 freshly frozen HCC tissue samples and matched peritumoral tissue samples were evaluated with a one-step qPCR test and immunohistochemical (IHC) analysis was conducted on 156 HCC samples to investigate the relationships among Eg5 expression, clinicopathological factors, and prognosis. Eg5 mRNA and protein expression levels were significantly higher in HCC tissues relative to matched noncancerous tissues (). High Eg5 protein expression was significantly related to liver cirrhosis () and TNM stage (). Kaplan-Meier survival and Cox regression analyses revealed that Eg5 overexpression (), liver cirrhosis (), and TNM stage () were independent prognostic factors for overall survival. These findings indicate that Eg5 expression can be used as a biomarker of poor prognosis and as a novel therapeutic target for HCC.